Research in Parkinson’s disease
Parkinson’s disease is one of the major neurodegenerative disease rampantly growing in incidence globally, which is caused by aggregation of abnormal proteins in the brain that jeopardize the cells that secrete dopamine, a chemical concoction required for neuronal function relevant to mainly locomotor systems, but with involvement of other functions of the brain as well. Recent evidence point to the gut dysbiosis due to exposure to toxic substances, over dosage of antibiotics etc as an etiology. Based on our earlier study in which Enterobacteriaceae and E.coli, the harmful bacteria leading to gut dysbiosis could be controlled in patients with Autism spectrum disorder with AFO-202 strain of Aureobasidium Pullulans produced beta 1,3-1,6 glucans, we conducted a pilot clinical study in patients with Parkinson’s disease. Oral consumption of the Nichi BRITE beta glucans for 90 days along with other standard of care medications yielded clinical improvements in terms of UPDRS score, constipation score and also in one of the patients a slight improvement in MRPI scale.